We have to be careful. This is what CYDY announce
Post# of 153773
(Total Views: 953)
Posted On: 05/23/2020 8:16:38 AM
We have to be careful. This is what CYDY announced:
This is what is being reported in some media and not what it says in the original press release. Haven’t found and official source but is different.
So, let’s temper expectations.
My opinion is that there is a new development that happened yesterday. What is it? In my order of possibilities:
1) Announcement of PDUFA date (CYDY received communication from FDA) in regards to HIV Combo application.
2) Announcement of BTD pre-meeting with FDA
3) Announcement of compassionate designation from FDA for COVID-19
4) Some sort of financial deal (hopefully with up list potential).
Obviously, if there is a CC there will be more information regarding enrollment in trials and international developments (Mexico, U.K., Taiwan) as a result of questions posed by participants. The list above is just the “magnet” of the meeting (why it was announced).
Have been wrong before and probably will be once more, but just my perspective of meeting outcomes for what is worth.
Regardless it will be likely a positive development. All I want to hear for the time being is trial enrollment numbers
Quote:
CytoDyn to Hold Conference Call to Provide Updates on COVID-19 (Phase 2, 3 & eIND), Cancer (mTNBC, Phase 2 for 22 Solid Tumor Cancers), HIV (BLA, Monotherapy), NASH, GvHD and MS
Download as PDFMay 22, 2020 8:49pm EDT
VANCOUVER, Washington, May 22, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company" , a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Nader Pourhassan, Ph.D., President and Chief Executive Officer, and Jacob Lalezari, M.D., Chief Science Officer, will host an investment community conference call on Tuesday, May 26, 2020 to provide a comprehensive update on several recent clinical and regulatory developments.
Management will dedicate approximately 30 minutes to address questions from analysts and investors.
This is what is being reported in some media and not what it says in the original press release. Haven’t found and official source but is different.
Quote:
CytoDyn to Hold Conference Call to Provide Updates on COVID-19 (Phase 2, 3 & eIND), Cancer (mTNBC, Phase 2 for 22 Solid Tumor Cancers), HIV (BLA, Monotherapy), NASH, GvHD and MS
So, let’s temper expectations.
My opinion is that there is a new development that happened yesterday. What is it? In my order of possibilities:
1) Announcement of PDUFA date (CYDY received communication from FDA) in regards to HIV Combo application.
2) Announcement of BTD pre-meeting with FDA
3) Announcement of compassionate designation from FDA for COVID-19
4) Some sort of financial deal (hopefully with up list potential).
Obviously, if there is a CC there will be more information regarding enrollment in trials and international developments (Mexico, U.K., Taiwan) as a result of questions posed by participants. The list above is just the “magnet” of the meeting (why it was announced).
Have been wrong before and probably will be once more, but just my perspective of meeting outcomes for what is worth.
Regardless it will be likely a positive development. All I want to hear for the time being is trial enrollment numbers
(3)
(0)